CytoMed Therapeutics Limited (GDTC) Cash Flow Statement
Where GDTC’s cash came from and went, 2025
December 31, 2025 · Singapore dollars- Cash from operations
- −S$3.7M
- Capital expenditures
- S$703,134 220.3% of revenue
- Free cash flow
- −S$4.4M −1,378.6% margin
- Returned to shareholders
- —
- Change in cash
- −S$2.6M cash at year-end S$2.1M
Cash from operations
−S$3.7M
Capital expenditures
−S$703,134
Investments (net)
+S$273,320
Acquisitions & other
+S$1.4M
Net borrowing (repayment)
−S$53,540
Shares issued
+S$283,094
Other financing
−S$20,906
Currency & other
−S$42,026
Change in cash
−S$2.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
GDTC operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
GDTC cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −S$640,5172019 | −S$3.7M2025 | — | |
| Capital expenditures | S$1.2M2019 | S$703,1342025 | −8.3%/yr | |
| Free cash flow | −S$1.8M2019 | −S$4.4M2025 | — | |
| Free cash flow margin | −2,441.0%2020 | −1,378.6%2025 | +1,062.4 pts | |
| Stock-based compensation | S$02023 | S$694,2002025 | — | |
| Dividends paid | S$02020 | S$02025 | — | |
| Capex / revenue | 546.0%2020 | 220.3%2025 | −325.7 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GDTC cash flow by activity
OperatingInvestingFinancingChange in cash
GDTC net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
GDTC cash flow statement in Singapore dollars
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −S$4.0M | −S$2.5M | −S$4.1M | −S$3.1M | −S$2.1M | −S$1.9M | −S$858,748 |
| Depreciation & amortization | S$401,584 | S$335,363 | S$381,148 | S$392,867 | S$330,648 | S$293,177 | S$179,185 |
| Stock-based compensation | S$694,200 | S$0 | S$0 | — | — | — | — |
| Change in working capital | −S$485,506 | −S$79,073 | −S$5,273 | −S$145,843 | −S$434,128 | −S$162,406 | −S$38,446 |
| Other non-cash items | −S$311,405 | −S$449,477 | S$227,472 | S$1.5M | S$442,937 | S$892,541 | S$77,492 |
| Cash from operating activities | −S$3.7M | −S$2.7M | −S$3.5M | −S$1.4M | −S$1.7M | −S$916,395 | −S$640,517 |
| Investing activities | |||||||
| Capital expenditures | −S$703,134 | −S$1.4M | −S$58,454 | −S$475,999 | −S$583,715 | −S$245,263 | −S$1.2M |
| Investments (net) | S$273,320 | S$1.1M | −S$2.8M | −S$473,305 | −S$823,666 | −S$513,054 | −S$247,899 |
| Acquisitions & other investing | S$1.4M | S$1.4M | S$156,661 | S$473,795 | S$581,790 | S$265,983 | S$247,899 |
| Cash from investing activities | S$929,283 | S$1.1M | −S$2.7M | −S$475,509 | −S$825,591 | −S$492,334 | −S$1.2M |
| Financing activities | |||||||
| Dividends paid | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | — |
| Net borrowing (repayment) | −S$53,540 | −S$44,579 | −S$340,426 | −S$128,759 | S$291,092 | S$1.5M | S$220,432 |
| Shares issued | S$283,094 | S$0 | S$11.3M | S$1.2M | S$2.0M | S$500,000 | S$0 |
| Other financing | −S$20,906 | −S$20,302 | −S$46,822 | −S$125,540 | S$1.9M | −S$80,326 | S$983,971 |
| Cash from financing activities | S$208,648 | −S$64,881 | S$10.9M | S$968,351 | S$4.2M | S$1.9M | S$1.2M |
| Summary | |||||||
| Net change in cash | −S$2.6M | −S$1.5M | S$4.6M | −S$942,128 | S$1.6M | S$886,632 | S$374,424 |
| Cash at end of period | S$2.1M | S$4.7M | S$6.2M | S$1.6M | S$2.5M | S$887,223 | S$374,424 |
| Free cash flow | −S$4.4M | −S$4.1M | −S$3.6M | −S$1.9M | −S$2.3M | −S$1.1M | −S$1.8M |
| Free cash flow margin | −1,378.6% | −5,912.5% | −707.0% | −514.5% | −2,733.1% | −2,441.0% | — |
| Capex / revenue | 220.3% | 2,014.2% | 11.5% | 130.2% | 693.4% | 546.0% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −S$1.8M | −S$885,226 | −S$1.7M | −S$868,349 | −S$2.2M | −S$1.1M | −S$724,934 | −S$543,941 | −S$545,630 | −S$1.5M | −S$989,175 | −S$1.1M |
| Depreciation & amortization | S$142,239 | S$118,383 | S$131,713 | S$111,062 | S$92,814 | S$89,939 | S$85,519 | S$83,394 | S$83,654 | S$38,231 | S$89,190 | S$101,642 |
| Stock-based compensation | — | S$7,468 | — | S$122,936 | — | — | — | — | — | — | — | — |
| Change in working capital | −S$113,837 | S$34,378 | −S$315,013 | −S$187,633 | −S$167,642 | −S$91,272 | −S$61,123 | S$20,657 | S$20,721 | S$275,587 | S$55,925 | −S$58,511 |
| Other non-cash items | S$89,209 | −S$97,873 | −S$135,065 | −S$227,166 | S$753,844 | S$324,384 | −S$88,222 | −S$137,843 | −S$138,204 | S$123,818 | S$93,962 | S$19,114 |
| Cash from operating activities | −S$1.7M | −S$822,870 | −S$2.0M | −S$1.0M | −S$1.5M | −S$801,449 | −S$788,760 | −S$577,733 | −S$579,459 | −S$1.0M | −S$750,098 | −S$1.0M |
| Investing activities | ||||||||||||
| Capital expenditures | −S$186,921 | −S$93,230 | −S$297,959 | −S$145,026 | −S$335,284 | −S$174,305 | −S$248,755 | −S$454,841 | −S$456,253 | −S$30,367 | −S$20,619 | −S$8,571 |
| Acquisitions & other investing | S$530,096 | S$115,775 | S$1.2M | S$620,951 | S$245,990 | S$162,995 | S$1.8M | −S$1.4M | −S$490,126 | — | S$1.4M | −S$8,778 |
| Cash from investing activities | S$343,175 | S$22,545 | S$854,545 | S$475,925 | −S$89,294 | −S$11,310 | S$1.5M | −S$1.9M | −S$946,379 | — | S$1.4M | −S$17,349 |
| Financing activities | ||||||||||||
| Shares issued | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 | S$0 |
| Other financing | S$675,451 | S$481,832 | S$252,653 | S$121,759 | −S$23,677 | −S$17,475 | −S$17,940 | −S$19,856 | −S$14,809 | −S$78,423 | −S$257 | S$11.1M |
| Cash from financing activities | S$675,451 | S$481,832 | S$252,653 | S$121,759 | −S$23,677 | −S$17,475 | −S$17,940 | −S$19,856 | −S$14,809 | −S$78,423 | −S$257 | S$11.1M |
| Summary | ||||||||||||
| Net change in cash | −S$642,588 | — | −S$786,975 | — | −S$1.5M | −S$923,195 | S$748,110 | −S$2.7M | −S$1.5M | −S$893,467 | −S$5.1M | S$9.9M |
| Cash at end of period | S$1.4M | S$2.1M | S$2.1M | S$2.9M | S$2.9M | S$2.5M | S$5.2M | S$6.6M | S$5.3M | S$6.8M | −S$1.5M | S$11.5M |
| Free cash flow | −S$1.8M | −S$916,100 | −S$2.3M | −S$1.2M | −S$1.8M | −S$975,754 | −S$1.0M | −S$1.0M | −S$1.0M | −S$1.1M | −S$770,720 | −S$1.0M |
| Free cash flow margin | −1,169.6% | −483.6% | −1,397.7% | −582.3% | −1,348.7% | −724.3% | −732.2% | −921.6% | −921.6% | — | −688.4% | −721.6% |
| Capex / revenue | 118.5% | 49.2% | 177.4% | 70.7% | 248.5% | 129.4% | 175.5% | 406.0% | 406.0% | — | 18.4% | 6.0% |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in Singapore dollars as reported; data from EODHD.
GDTC cash generation
In fiscal 2025 (ended December 31, 2025), CytoMed Therapeutics generated -S$3.7 million of cash from operations and spent S$0.7 million on capital expenditures, leaving free cash flow of -S$4.4 million, −1,378.6% of revenue. Cash and equivalents fell by S$2.6 million over the year.
Related: GDTC income statement, GDTC balance sheet. See the GDTC stock overview for the latest quote and news.
GDTC cash flow FAQ
What is CytoMed Therapeutics's free cash flow?
CytoMed Therapeutics's free cash flow was -S$4.4 million in fiscal 2025: -S$3.7 million of operating cash flow minus S$0.7 million of capital expenditures It was -S$4.1 million a year earlier..
How much cash does CytoMed Therapeutics generate from operations?
CytoMed Therapeutics generated -S$3.7 million of cash from operating activities in fiscal 2025.
How much does CytoMed Therapeutics spend on capital expenditures?
CytoMed Therapeutics spent S$0.7 million on capital expenditures in fiscal 2025, 220.3% of revenue, compared with S$1.4 million the year before.